Literature DB >> 30730756

The Addition of Hip Arthroscopy to Periacetabular Osteotomy Does Not Increase Complication Rates: A Prospective Case Series.

Casey M Sabbag1, Jeffrey J Nepple2, Cecilia Pascual-Garrido2, Gopal R Lalchandani2, John C Clohisy2, Rafael J Sierra1.   

Abstract

BACKGROUND: Previous studies on periacetabular osteotomy (PAO) reported complication and reoperation rates of 5.9% and 10%, respectively. Hip arthroscopy is increasingly utilized as an adjunct procedure to PAO to precisely treat associated intra-articular pathology. The addition of this procedure has the potential of further increasing complication rates.
PURPOSE: To determine the rates of complication and reoperation of combined hip arthroscopy and PAO for the treatment of acetabular deformities and associated intra-articular lesions. STUDY
DESIGN: Case series; Level of evidence, 4.
METHODS: Using a prospective database, the authors retrospectively reviewed 248 hips (240 patients) that underwent combined hip arthroscopy and PAO between 2007 and 2016. Data were collected at scheduled follow-up visits at approximately 1 month, 3 to 4 months, and 1 and 2 years after surgery. Mean follow-up from surgery was 3 years (range, 1-8 years). A total of 220 PAOs were done for symptomatic acetabular dysplasia, 18 for symptomatic acetabular retroversion, and 10 for combined acetabular dysplasia and acetabular retroversion. Central compartment arthroscopy was performed for treatment of intra-articular chondrolabral pathology in all cases. Select cases underwent femoral head-neck junction osteochondroplasty either arthroscopically before the PAO or through an open approach after it. Complications were graded according to the modified Dindo-Clavien complication scheme, which was validated for hip preservation procedures. Reoperations (excluding hardware removal) were recorded.
RESULTS: Grade III complications occurred among 7 patients (3%) while there were no grade IV complications. Grade III complications included deep infection (n = 3), wound dehiscence (n = 1), hematoma requiring exploration (n = 1), symptomatic heterotopic ossification requiring excision (n = 1), and deep venous thrombosis (n = 1). There were 13 reoperations (5%), and 3 were repeat hip arthroscopy. Univariate Cox hazard models were used to estimate the relative risk factors for complication and reoperation. Increased age (per decade) showed over twice the increased likelihood for complications (hazard ratio, 2.5; 95% CI, 1.67-3.74). Also, preoperative diagnosis of acetabular retroversion, not acetabular dysplasia, showed >3 times the increased risk of reoperation (hazard ratio, 3.05; 95% CI, 1.41-6.61).
CONCLUSION: The rate of complications reported is comparable (3%) with previously published complication rates of PAO without hip arthroscopy. In this cohort, increasing age and diagnosis of acetabular retroversion were associated with higher complication and reoperation rates.

Entities:  

Keywords:  Dindo-Clavien; complications; hip arthroscopy; periacetabular osteotomy; reoperations

Mesh:

Year:  2019        PMID: 30730756     DOI: 10.1177/0363546518820528

Source DB:  PubMed          Journal:  Am J Sports Med        ISSN: 0363-5465            Impact factor:   6.202


  11 in total

1.  Hip Arthroscopy Prior to Periacetabular Osteotomy Does Not Increase Operative Time or Complications: A Single Center Experience.

Authors:  Alan G Shamrock; Robert W Westermann; Trevor R Gulbrandsen; Zain M Khazi; Christopher N Carender; Michael C Willey
Journal:  Iowa Orthop J       Date:  2021

2.  Hip arthroscopy after periacetabular osteotomy for acetabular dysplasia - incidence and clinical outcome.

Authors:  Pierre Laboudie; Thomas Dymond; Cheryl Kreviazuk; George Grammatopoulos; Paul E Beaulé
Journal:  BMC Musculoskelet Disord       Date:  2022-07-12       Impact factor: 2.562

Review 3.  Arthroscopic Treatment of Mild/Borderline Hip Dysplasia with Concomitant Femoroacetabular Impingement-Literature Review.

Authors:  Ran Atzmon; Marc R Safran
Journal:  Curr Rev Musculoskelet Med       Date:  2022-06-16

4.  A comparison of 6-month outcomes between periacetabular osteotomy with concomitant hip arthroscopy to isolated hip arthroscopy for femoroacetabular impingement.

Authors:  Thomas Ellis; Dave Kohlrieser; Brian Rao; Keelan Enseki; Adam Popchak; RobRoy L Martin
Journal:  Arch Orthop Trauma Surg       Date:  2021-04-18       Impact factor: 3.067

5.  What Mid-term Patient-reported Outcome Measure Scores, Reoperations, and Complications Are Associated with Concurrent Hip Arthroscopy and Periacetabular Osteotomy to Treat Dysplasia with Associated Intraarticular Abnormalities?

Authors:  Adam I Edelstein; Jeffrey J Nepple; Wahid Abu-Amer; Cecilia Pascual-Garrido; Charles W Goss; John C Clohisy
Journal:  Clin Orthop Relat Res       Date:  2021-05-01       Impact factor: 4.176

Review 6.  Systematic review of pre-operative planning modalities for correction of acetabular dysplasia.

Authors:  Alexander J Acuña; Linsen T Samuel; Bilal Mahmood; Atul F Kamath
Journal:  J Hip Preserv Surg       Date:  2019-11-28

Review 7.  Heterotopic Ossification After Arthroscopic Procedures: A Scoping Review of the Literature.

Authors:  Liang Zhou; Shawn M Gee; Joshua A Hansen; Matthew A Posner
Journal:  Orthop J Sports Med       Date:  2022-01-18

8.  Combined Hip Arthroscopy and Periacetabular Osteotomy (PAO): Technical Focus on Arthroscopically Elevating the Iliocapsularis and Performing the Open PAO.

Authors:  Andrea M Spiker; Elizabeth H G Turner; Itai Gans; Haley I Sisel; Benjamin R Wiseley; David C Goodspeed
Journal:  Arthrosc Tech       Date:  2021-09-21

9.  Incidence of Heterotopic Ossification with NSAID Prophylaxis Is Low After Open and Arthroscopic Hip Preservation Surgery.

Authors:  Andrew L Schaver; Michael C Willey; Robert W Westermann
Journal:  Arthrosc Sports Med Rehabil       Date:  2021-07-29

10.  Single Table Concomitant Post-Less Hip Arthroscopy Combined with Periacetabular Osteotomy for Hip Dysplasia.

Authors:  Dustin Woyski; Steve Olson; Brian Lewis
Journal:  Arthrosc Tech       Date:  2019-11-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.